ANTIMICROBIAL AGENTS NEOMYCIN First draft prepared by Dr K.N. Woodward Veterinary Medicines Directorate Ministry of Agriculture, Fisheries and Food Addlestone, Surrey, United Kingdom 1. Explanation 2. Biological data 2.1 Toxicological studies 2.1.1 Special studies on genotoxicity 3. Comments 4. Evaluation 5. References 1. EXPLANATION Neomycin is an aminoglycoside antibiotic that was previously evaluated at the forty-third meeting of the Committee (Annex 1, reference 113). At that time the Committee established a temporary ADI of 0-30 µg/kg bw based on the NOEL of 6 mg/kg bw per day for ototoxicity in a 90-day study on the guinea-pig and a safety factor of 200. The ADI was made temporary in view of deficiencies in the genotoxicity data. The in vitro genotoxicity data available at the forty-third meeting indicated that neomycin causes chromosomal aberrations, but only a limited number of studies were available and these had been poorly performed. This monograph addendum summarizes the data that have become available since the previous evaluation. 2. BIOLOGICAL DATA 2.1 Toxicological studies 2.1.1 Special studies on genotoxicity The results of the further genotoxicity studies with neomycin are summarized in Table 1. Neomycin was negative in the Ames Salmonella typhimurium reverse mutation assay, although the maximum concentration used was limited to 75 µg/plate, owing to cytotoxicity. Similarly, a negative result was obtained in a reversion assay with Escherichia coli WP2 uvrA, but again the maximum concentration was limited by cytotoxicity to 75 µg/plate. However, in a test for point mutations using Chinese hamster ovary cells (HGPRT locus), negative results were obtained with concentrations of up to 5000 µg/ml. A negative result was obtained in a cytogenetics test in mice where animals were given repeated intraperitoneal doses of up to 200 mg/kg bw per day. No studies were presented to show that neomycin distributes to bone marrow, but aminoglycosides are widely distributed in the body following absorption and it is highly likely, taking into account vascular perfusion of bone marrow, that the drug reached the target cells. The data indicate that neomycin is not genotoxic. Table 1. Results of genotoxicity studies on neomycin Test system Test object Concentration Results Reference Reverse Salmonella typhimurium 0.93-75 - Mayo et al., mutation1 TA97A, TA98, TA100, µ/plate 1995 TA1535 Escherichia coli 0.93-75 - Mayo et al., WP2 uvrA µg/plate 1995 Forward Chinese hamster 0-5000 - Mayo & mutation1 ovary cells, µg/ml Aaron, 1995a HGPRT locus In vivo mouse bone 0-200/250 - Mayo & cytogenetics test marrow mg/kg bw Aaron, 1995b per day 1 with and without rat liver metabolic activation (S9) 3. COMMENTS The new data on genotoxicity considered by the Committee consisted of the results of a reverse mutation assay using Salmonella typhimurium and Escherichia coli, a forward mutation assay in Chinese hamster ovary cells, and an in vivo bone marrow cytogenetic assay in mice. All gave negative results. The Committee concluded from these results that neomycin is not genotoxic. 4. EVALUATION The Committee established an ADI of 0-60 µg/kg bw, based on the NOEL of 6 mg/kg bw per day for ototoxicity in the guinea-pig and a safety factor of 100. 5. REFERENCES Mayo, J.K. & Aaron, C.S. (1995a). U-4567 (Neomycin Sulfate): Evaluation of U-4567 (Neomycin sulfate) in the ASA52/XPRT mammalian cell mutation assay with and without metabolic activation. Unpublished report No. 7228-95-125. Submitted to WHO by Pharmacia and Upjohn Company, Kalamazoo, MI, USA. Mayo, J.K. & Aaron, C.S. (1995b). U-4567 (Neomycin sulfate): Evaluation of U-4567 (Neomycin sulfate) in the acute test for chemical induction of chromosome aberration in mouse bone marrow cells in vivo. Unpublished report No. 7228-95-130. Submitted to WHO by Pharmacia and Upjohn Company, Kalamazoo, MI, USA. Mayo, J.K., Smith, A.L, & Aaron, C.S. (1995). Neomycin sulfate (U-4567): Evaluation of neomycin sulfate (U-4567) in the preincubation mutagenesis assay in bacteria (Ames Assay). Unpublished report No. 7228-94-133. Submitted to WHO by Pharmacia and Upjohn Company, Kalamazoo, MI, USA.
See Also: Toxicological Abbreviations Neomycin (JECFA Food Additives Series 51) Neomycin (WHO Food Additives Series 34) NEOMYCIN (JECFA Evaluation)